1010086--3/13/2008--SIGA_TECHNOLOGIES

related topics

{product, candidate, development}

{stock, price, share}

{product, liability, claim}

{property, intellectual, protect}

{acquisition, growth, future}

{provision, law, control}

{regulation, government, change}

{control, financial, internal}

{cost, regulation, environmental}

{competitive, industry, competition}

{cost, operation, labor}

We have incurred operating losses since our inception and expect to incur net losses and negative cash flow for the foreseeable future. Our business will suffer if we are unable to raise additional equity funding. Our stock price is, and we expect it to remain, volatile, which could limit investors ability to sell stock at a profit. We are in various stages of product development and there can be no assurance of successful commercialization. Most of our immediately foreseeable future revenues are contingent upon grants and contracts from the United States government and collaborative and license agreements and we may not achieve sufficient revenues from these agreements to attain profitability. The biopharmaceutical market in which we compete and will compete is highly competitive. Because we must obtain regulatory clearance to test and market our products in the United States, we cannot predict whether or when we will be permitted to commercialize our products. If our technologies or those of our collaborators are alleged or found to infringe the patents or proprietary rights of others, we may be sued or have to license those rights from others on unfavorable terms. Our ability to compete may decrease if we do not adequately protect our intellectual property rights. We may have difficulty managing our growth. Our activities involve hazardous materials and may subject us to environmental regulatory liabilities. Our potential products may not be acceptable in the market or eligible for third-party reimbursement resulting in a negative impact on our future financial results. If our products harm people, we may experience product liability claims that may not be covered by insurance. We may be required to perform additional clinical trials or change the labeling of our products if we or others identify side effects after our products are on the market, which could harm sales of the affected products. The manufacture of biotechnology products can be a time-consuming and complex process which may delay or prevent commercialization of our products, or may prevent our ability to produce an adequate volume for the successful commercialization of our products. Healthcare reform and controls on healthcare spending may limit the price we charge for any products and the amounts thereof that we can sell. The future issuance of preferred stock may adversely affect the rights of the holders of our common stock. Concentration of ownership of our capital stock could delay or prevent change of control.

Full 10-K form ▸

1010086--3/13/2008--SIGA_TECHNOLOGIES_INC